2-{3-[4-(Alkylsulfinyl) phenyl]-1-benzofuran-5-yl}-5-methyl-1, 3, 4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β with good brain …
…, J Kunitomo, E Kimura, H Iwashita, Y Uno…
Index: Saitoh, Morihisa; Kunitomo, Jun; Kimura, Eiji; Iwashita, Hiroki; Uno, Yumiko; Onishi, Tomohiro; Uchiyama, Noriko; Kawamoto, Tomohiro; Tanaka, Toshimasa; Mol, Clifford D.; Dougan, Douglas R.; Textor, Garret P.; Snell, Gyorgy P.; Takizawa, Masayuki; Itoh, Fumio; Kori, Masakuni Journal of Medicinal Chemistry, 2009 , vol. 52, # 20 p. 6270 - 6286
Full Text: HTML
Citation Number: 66
Abstract
Glycogen synthase kinase 3β (GSK-3β) inhibition is expected to be a promising therapeutic approach for treating Alzheimer's disease. Previously we reported a series of 1, 3, 4- oxadiazole derivatives as potent and highly selective GSK-3β inhibitors, however, the representative compounds 1a, b showed poor pharmacokinetic profiles. Efforts were made to address this issue by reducing molecular weight and lipophilicity, leading to the ...
Related Articles:
[Van Otterlo, Willem A.L.; Morgans, Garreth L.; Madeley, Lee G.; Kuzvidza, Samuel; Moleele, Simon S.; Thornton, Natalie; De Koning, Charles B. Tetrahedron, 2005 , vol. 61, # 32 p. 7746 - 7755]
[Journal of Medicinal Chemistry, , vol. 40, # 3 p. 322 - 330]
[Journal of Medicinal Chemistry, , vol. 40, # 3 p. 322 - 330]
[Tetrahedron, , vol. 61, # 32 p. 7746 - 7755]
[Tetrahedron, , vol. 61, # 32 p. 7746 - 7755]